Kopetz S et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381(17):1632-43. Abstract

Kopetz S et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015;33(34):4032-8. Abstract

US Food and Drug Administration. FDA approves new dosing regimen for cetuximab [press release]. April 6, 2021. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-cetuximab.

Van Cutsem E et al. ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer. ESMO GI 2021;Abstract O-10.

Yao Z et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 2017;548(7666):234-8. Abstract